Topic - David Blaszczak

Subscribe to this topic via RSS or ATOM
Related Stories
  • No Stories Found

More Stories →

  • "CMS will never admit that cost is a part of the reason they opened up the national coverage decision, but I think it definitely is," said David Blaszczak, a Potomac Research Group analyst who previously worked for the agency. "If this product was only $200 we wouldn't be going through this process."

    Medicare panel backs costly cancer drug Provenge →

Happening Now